Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.30
SNY's Cash to Debt is ranked lower than
51% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. SNY: 0.30 )
SNY' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: 0.3

Equity to Asset 0.57
SNY's Equity to Asset is ranked higher than
64% of the 728 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. SNY: 0.57 )
SNY' s 10-Year Equity to Asset Range
Min: 0.46   Max: 0.65
Current: 0.57

0.46
0.65
Interest Coverage 8.34
SNY's Interest Coverage is ranked higher than
53% of the 454 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.71 vs. SNY: 8.34 )
SNY' s 10-Year Interest Coverage Range
Min: 8.34   Max: 19.65
Current: 8.34

8.34
19.65
F-Score: 5
Z-Score: 2.31
M-Score: -2.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 15.33
SNY's Operating margin (%) is ranked higher than
84% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.25 vs. SNY: 15.33 )
SNY' s 10-Year Operating margin (%) Range
Min: -2.03   Max: 38.21
Current: 15.33

-2.03
38.21
Net-margin (%) 11.16
SNY's Net-margin (%) is ranked higher than
81% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. SNY: 11.16 )
SNY' s 10-Year Net-margin (%) Range
Min: -24   Max: 25.8
Current: 11.16

-24
25.8
ROE (%) 6.53
SNY's ROE (%) is ranked higher than
71% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. SNY: 6.53 )
SNY' s 10-Year ROE (%) Range
Min: -10.15   Max: 32.83
Current: 6.53

-10.15
32.83
ROA (%) 3.87
SNY's ROA (%) is ranked higher than
73% of the 777 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. SNY: 3.87 )
SNY' s 10-Year ROA (%) Range
Min: -4.7   Max: 21.3
Current: 3.87

-4.7
21.3
ROC (Joel Greenblatt) (%) 32.17
SNY's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.60 vs. SNY: 32.17 )
SNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2.98   Max: 111.43
Current: 32.17

-2.98
111.43
Revenue Growth (%) 0.50
SNY's Revenue Growth (%) is ranked higher than
61% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. SNY: 0.50 )
SNY' s 10-Year Revenue Growth (%) Range
Min: 0.5   Max: 27.4
Current: 0.5

0.5
27.4
EBITDA Growth (%) -2.00
SNY's EBITDA Growth (%) is ranked higher than
64% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. SNY: -2.00 )
SNY' s 10-Year EBITDA Growth (%) Range
Min: -10   Max: 49.1
Current: -2

-10
49.1
EPS Growth (%) -12.70
SNY's EPS Growth (%) is ranked higher than
62% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. SNY: -12.70 )
SNY' s 10-Year EPS Growth (%) Range
Min: -12.7   Max: 41.2
Current: -12.7

-12.7
41.2
» SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SNY Guru Trades in Q3 2013

James Barrow 21,466,988 sh (+312.86%)
Mario Gabelli 5,950 sh (+32.22%)
HOTCHKIS & WILEY 4,786,334 sh (+31.71%)
Sarah Ketterer 114,118 sh (+29.1%)
Third Avenue Management 13,830 sh (+4.85%)
PRIMECAP Management 2,284,031 sh (+4.57%)
Manning & Napier Advisors, Inc 323,315 sh (+2.37%)
Ken Fisher 12,828,009 sh (+0.15%)
John Hussman 22,100 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Jean-Marie Eveillard 653,662 sh (unchged)
Chuck Royce Sold Out
Dodge & Cox 43,966,249 sh (-0.42%)
Charles Brandes 1,701,970 sh (-0.66%)
NWQ Managers 5,425,020 sh (-3.25%)
Warren Buffett 3,905,875 sh (-3.88%)
» More
Q4 2013

SNY Guru Trades in Q4 2013

Sarah Ketterer 431,317 sh (+277.96%)
HOTCHKIS & WILEY 5,912,375 sh (+23.53%)
Charles Brandes 2,013,300 sh (+18.29%)
Third Avenue Management 16,105 sh (+16.45%)
NWQ Managers 5,832,760 sh (+7.52%)
James Barrow 22,645,140 sh (+5.49%)
Jean-Marie Eveillard 654,462 sh (+0.12%)
John Hussman 22,100 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Ken Fisher 12,818,390 sh (-0.07%)
PRIMECAP Management 2,281,231 sh (-0.12%)
Dodge & Cox 43,628,729 sh (-0.77%)
Manning & Napier Advisors, Inc 312,008 sh (-3.5%)
Mario Gabelli 4,500 sh (-24.37%)
» More
Q1 2014

SNY Guru Trades in Q1 2014

Scott Black 247,100 sh (New)
Bill Nygren 2,600,000 sh (New)
John Buckingham 20,080 sh (New)
Steven Cohen 300,000 sh (New)
Manning & Napier Advisors, Inc 2,923,087 sh (+836.86%)
HOTCHKIS & WILEY 9,804,594 sh (+65.83%)
James Barrow 27,790,116 sh (+22.72%)
Sarah Ketterer 506,901 sh (+17.52%)
PRIMECAP Management 2,476,856 sh (+8.58%)
Charles Brandes 2,072,790 sh (+2.95%)
Ken Fisher 12,926,402 sh (+0.84%)
Dodge & Cox 43,664,887 sh (+0.08%)
Mario Gabelli 4,500 sh (unchged)
Murray Stahl 26,000 sh (unchged)
John Hussman 22,100 sh (unchged)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Third Avenue Management 15,706 sh (-2.48%)
NWQ Managers 5,460,055 sh (-6.39%)
Jean-Marie Eveillard 610,749 sh (-6.68%)
» More
Q2 2014

SNY Guru Trades in Q2 2014

Bill Nygren 4,950,000 sh (+90.38%)
PRIMECAP Management 3,011,646 sh (+21.59%)
Sarah Ketterer 567,921 sh (+12.04%)
Charles Brandes 2,182,305 sh (+5.28%)
James Barrow 28,526,802 sh (+2.65%)
John Buckingham 20,344 sh (+1.31%)
Manning & Napier Advisors, Inc 2,961,185 sh (+1.3%)
Ken Fisher 13,079,575 sh (+1.18%)
Mario Gabelli 4,500 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
John Hussman Sold Out
Dodge & Cox 43,549,909 sh (-0.26%)
HOTCHKIS & WILEY 9,772,061 sh (-0.33%)
Jean-Marie Eveillard 608,568 sh (-0.36%)
Third Avenue Management 13,402 sh (-14.67%)
Scott Black 178,985 sh (-27.57%)
NWQ Managers 2,602,503 sh (-52.34%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Scott Black 2014-06-30 Reduce -27.57%0.39%$51.23 - $54.54 $ 54.73%178985
John Hussman 2014-06-30 Sold Out 0.09%$51.23 - $54.54 $ 54.73%0
PRIMECAP Management 2014-06-30 Add 21.59%0.03%$51.23 - $54.54 $ 54.73%3011646
Scott Black 2014-03-31 New Buy1.4%$47.77 - $53.63 $ 54.78%247100
James Barrow 2014-03-31 Add 22.72%0.39%$47.77 - $53.63 $ 54.78%27790116
Charles Brandes 2013-12-31 Add 18.29%0.2%$48.75 - $54 $ 54.76%2013300
Mario Gabelli 2013-12-31 Reduce -24.37%$48.75 - $54 $ 54.76%4500
James Barrow 2013-09-30 Add 312.86%1.29%$47.64 - $53.24 $ 54.78%21466988
Mario Gabelli 2013-09-30 Add 32.22%$47.64 - $53.24 $ 54.78%5950
Charles Brandes 2013-06-30 Reduce -20.35%0.26%$49.77 - $55.64 $ 54.73%1713266
Mario Gabelli 2013-06-30 New Buy$49.77 - $55.64 $ 54.73%4500
Charles Brandes 2012-09-30 Reduce -25.37%0.41%$36.81 - $44.6 $ 54.735%2982819
David Dreman 2012-09-30 Sold Out 0.09%$36.81 - $44.6 $ 54.735%0
John Hussman 2012-06-30 Add 22.62%$33.4 - $39.06 $ 54.752%27100
PRIMECAP Management 2012-03-31 Add 141.26%0.08%$35.32 - $38.92 $ 54.756%2222692
George Soros 2011-12-31 Sold Out 0.11%$31.72 - $37.45 $ 54.759%0
James Barrow 2011-12-31 Add 26.83%0.08%$31.72 - $37.45 $ 54.759%4501475
James Barrow 2011-09-30 Add 83.96%0.13%$31.5 - $40.08 $ 54.752%3549200
George Soros 2011-09-30 New Buy0.11%$31.5 - $40.08 $ 54.752%201400
Dodge & Cox 2011-06-30 Add 6.63%0.16%$35.68 - $40.58 $ 54.744%54287695
James Barrow 2011-06-30 Add 43.65%0.05%$35.68 - $40.58 $ 54.744%1929300
David Dreman 2011-06-30 Add 38.36%0.02%$35.68 - $40.58 $ 54.744%96767
John Hussman 2011-06-30 Add 39.68%$35.68 - $40.58 $ 54.744%17600
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Sanofi

Bill Nygren Comments on Sanofi - Apr 08, 2014

Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Sanofi

Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks
sing the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies were bought by the largest numbers of gurus over a certain period of time. By using this screener, we filtered down to see which companies based in Europe were held by the highest number of gurus. Read more...
Oakmark Funds' Bill Nygren Buys 4 New Stocks
Bill Nygren (Trades, Portfolio)’s Oakmark fund beat the S&P 500 for the first quarter with a 5% gain compared to the index’s 2% rise. In his first quarter letter, he attributed the strong quarter primarily to Forest Laboratories being acquired by Actavis Plc (ACT), and large exposure to auto-related cyclical and financials. Read more...
Bill Nygren Comments on Sanofi
Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%. Read more...
Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies were bought by the largest numbers of gurus over a certain period of time. By using this screener, we filtered down to see which companies based in Europe were bought by the highest number of gurus. Read more...
Warren Buffett Shows Changes to International Stocks: Tesco, Munich Re, Sanofi, POSCO
Warren Buffett (Trades, Portfolio) reported the holding changes at Berkshire Hathaway (BRK.A)(BRK.B) last month, but he did not include his foreign stocks, as he is not required to by the SEC. Once a year, in his annual letters, however, he gives a glimpse of his international dealings by reporting the status of all his equity positions exceeding $1 billion in value. The latest letter, reported last week, revealed some notable changes in his international holdings. Read more...
Top Guru-Held European Companies as of the Second Quarter
By using the Aggregated Portfolio Screener, we filtered through the 51 highest rated gurus to find out what international companies they liked the best. The following companies are each held by 10 gurus as of the second quarter. [b] Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.80
SNY's P/E(ttm) is ranked higher than
82% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.30 vs. SNY: 26.80 )
SNY' s 10-Year P/E(ttm) Range
Min: 9.64   Max: 402.35
Current: 26.8

9.64
402.35
P/B 2.14
SNY's P/B is ranked higher than
76% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. SNY: 2.14 )
SNY' s 10-Year P/B Range
Min: 1.11   Max: 7.02
Current: 2.14

1.11
7.02
P/S 3.35
SNY's P/S is ranked higher than
65% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. SNY: 3.35 )
SNY' s 10-Year P/S Range
Min: 1.77   Max: 5.42
Current: 3.35

1.77
5.42
PFCF 18.04
SNY's PFCF is ranked higher than
92% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. SNY: 18.04 )
SNY' s 10-Year PFCF Range
Min: 6.66   Max: 24.81
Current: 18.04

6.66
24.81
EV-to-EBIT 20.33
SNY's EV-to-EBIT is ranked higher than
83% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.72 vs. SNY: 20.33 )
SNY' s 10-Year EV-to-EBIT Range
Min: 10.5   Max: 204.2
Current: 20.33

10.5
204.2
Shiller P/E 22.80
SNY's Shiller P/E is ranked higher than
83% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 150.63 vs. SNY: 22.80 )
SNY' s 10-Year Shiller P/E Range
Min: 13.28   Max: 25.3
Current: 22.8

13.28
25.3
Current Ratio 1.43
SNY's Current Ratio is ranked higher than
53% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. SNY: 1.43 )
SNY' s 10-Year Current Ratio Range
Min: 0.81   Max: 2.71
Current: 1.43

0.81
2.71
Quick Ratio 0.96
SNY's Quick Ratio is ranked higher than
52% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. SNY: 0.96 )
SNY' s 10-Year Quick Ratio Range
Min: 0.46   Max: 2.41
Current: 0.96

0.46
2.41

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.50
SNY's Dividend Yield is ranked higher than
93% of the 458 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. SNY: 3.50 )
SNY' s 10-Year Dividend Yield Range
Min: 1.66   Max: 5.39
Current: 3.5

1.66
5.39
Dividend Payout 0.89
SNY's Dividend Payout is ranked higher than
67% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. SNY: 0.89 )
SNY' s 10-Year Dividend Payout Range
Min: 1.17   Max: 8.15
Current: 0.89

1.17
8.15
Dividend growth (3y) 4.90
SNY's Dividend growth (3y) is ranked higher than
81% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -0.10 vs. SNY: 4.90 )
SNY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 22.1
Current: 4.9

0
22.1
Yield on cost (5-Year) 4.64
SNY's Yield on cost (5-Year) is ranked higher than
92% of the 466 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. SNY: 4.64 )
SNY' s 10-Year Yield on cost (5-Year) Range
Min: 2.2   Max: 7.15
Current: 4.64

2.2
7.15
Share Buyback Rate -0.80
SNY's Share Buyback Rate is ranked higher than
77% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. SNY: -0.80 )
SNY' s 10-Year Share Buyback Rate Range
Min: 1.3   Max: -24.6
Current: -0.8

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.06
SNY's Price/DCF (Projected) is ranked higher than
94% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.06 vs. SNY: 1.06 )
SNY' s 10-Year Price/DCF (Projected) Range
Min: 0.61   Max: 7.5
Current: 1.06

0.61
7.5
Price/Median PS Value 1.17
SNY's Price/Median PS Value is ranked higher than
74% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. SNY: 1.17 )
SNY' s 10-Year Price/Median PS Value Range
Min: 0.64   Max: 8.62
Current: 1.17

0.64
8.62
Earnings Yield (Greenblatt) 4.90
SNY's Earnings Yield (Greenblatt) is ranked higher than
74% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. SNY: 4.90 )
SNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 9.5
Current: 4.9

0.5
9.5
Forward Rate of Return (Yacktman) 4.34
SNY's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 633 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.43 vs. SNY: 4.34 )
SNY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 5.3   Max: 62.9
Current: 4.34

5.3
62.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0O59.country, SAN.France, SANF.Italy, SNW2.Germany, SNW.Germany, SNYNF.USA
Sanofi was incorporated under the laws of France in 1994. It is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company also discovers, develops and distributes therapeutic solutions. The Company is engaged in offering solutions across areas of core historical strength and multiple growth platforms. Within its Pharmaceuticals business, it focuses on various areas which include diabetes, rare diseases, oncology, and other flagship products in anti-thrombotics, cardiovascular, renal and biosurgery fields. The Company is facing competition from generics for several of its major products, in an environment subject to cost containment pressures from both third party payers and healthcare authorities. The manufacturing and research operations of the Company is subject to increasingly stringent health, safety and environmental (HSE) laws and regulations. The Company has core strengths in healthcare, with 7 growth platforms which includes diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Through the acquisition of Genzyme, the Company has strongly reinforced its footprint in rare diseases.
» More Articles for NYSE:SNY

Headlines

Articles On GuruFocus.com
Sarah Ketterer’s Causeway International Value Fund Reports Top Five Aug 31 2014 
The French Government Collapses…and French Stocks Rally. What Gives? Aug 26 2014 
Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Aug 23 2014 
Sanofi Doesn´t Look Good in Absolute Valuation Method Aug 21 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
George Soros Reveals His Largest Stake Jul 23 2014 
Health Care Sector in an Upward Climb in June Jun 12 2014 
Sarah Ketterer’s Causeway International Value’s Top Five Holdings Jun 05 2014 
Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks May 29 2014 


More From Other Websites
Cholesterol Drug Halves Heart Attack and Stroke in Early Test Aug 31 2014
Early Hint At Cardiovascular Outcomes With Sanofi's and Regeneron's Rapidly Advancing Cholesterol... Aug 31 2014
SIGNIFY Trial Provokes Sound And Fury Over Controversial Servier and Amgen Drug Aug 31 2014
Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab... Aug 31 2014
Regeneron and Sanofi Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab... Aug 31 2014
Regeneron Pharmaceuticals' Pipeline Progress Raises Costs Aug 29 2014
Amgen: Why Its New Drug Application is a Big Deal Aug 28 2014
There Are 2000 Reasons For Continued Optimism In The Stock Market Aug 28 2014
The Zacks Analyst Blog Highlights: RadioShack, Amicus Therapeutics, Sanofi, Shire and Gilead... Aug 28 2014
Where Are the Opportunities in U.S. Health Care? Aug 27 2014
Return to Behemoth Stocks Aug 27 2014
The 4 Companies Teaming Up For A New Tool To Fight Cancer Aug 25 2014
InterMune Stock Spikes On Rare Big Biotech Buyout Aug 25 2014
Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at... Aug 25 2014
Covance Retains Balanced View on Steady Growth Aug 22 2014
AstraZeneca Updates on PLATO Study Investigation on Brilinta Aug 22 2014
Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day Aug 22 2014
Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results Aug 21 2014
5 companies that will benefit from ALS awareness Aug 21 2014
Illumina Partners with AstraZeneca, Sanofi, Janssen in NGS Aug 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK